MAPT and Alzheimer disease: However, in a study comparing the effects of aducanumab and donanemab, participants above a 1.46 standardized uptake value ratio of tau protein threshold (high tau) showed no benefit in reduction in AD biomarkers after plaque clearance, indicating that donanemab may not be beneficial for patients with moderate to severe dementia [127].